Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Public Offering
The net proceeds from the sale of the shares was approximately $53.6 million. The Company plans to use the net proceeds from the offering (i) to fund clinical studies of Firdapse® for the treatment of MuSK-antibody positive Myasthenia Gravis (MuSK-MG) and Spinal Muscular Atrophy (SMA), (ii) to fund pre-commercialization activities for Firdapse®, and (iii) for general corporate purposes.
The shares were offered pursuant to a shelf registration statement on Form S-3
(File No. 333-219259) filed pursuant to the Securities Act of 1933, as amended, which was previously filed with, and declared effective by, the Securities and Exchange Commission. A prospectus supplement relating to the offering was filed with the SEC on
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Copies of the prospectus supplement and the accompanying prospectus relating to these securities are available on the Investor Relations section
of the Company's website and on the SEC's website located at http://www.sec.gov. Copies may also be obtained by contacting Piper Jaffray & Co., Attention:
Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2016, the prospectus supplement that Catalyst filed relating to the offering, and Catalyst's other filings with the
Brian Korb The Trout Group LLC(646) 378-2923 firstname.lastname@example.org Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 email@example.com Media Contacts David Schull Russo Partners(212) 845-4271 (212) 845-4272 firstname.lastname@example.org
News Provided by Acquire Media